Production (Stage)
Tonix Pharmaceuticals Holding Corp.
TNXP
$28.93
$2.539.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.14% | -31.68% | -29.26% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.14% | -31.68% | -29.26% | -- | -- |
| Cost of Revenue | -43.19% | -50.02% | -34.50% | -- | -- |
| Gross Profit | 80.78% | -0.92% | -21.55% | -- | -- |
| SG&A Expenses | 8.53% | 34.08% | -11.54% | 6.77% | 25.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.45% | -19.44% | -42.82% | -29.08% | -29.70% |
| Operating Income | 24.81% | 17.74% | 44.74% | 36.70% | 37.02% |
| Income Before Tax | -12.65% | 19.08% | 49.19% | -177.81% | 54.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.65% | 19.08% | 49.19% | -177.81% | 54.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.65% | 19.08% | 49.19% | -177.81% | 54.74% |
| EBIT | 24.81% | 17.74% | 44.74% | 36.70% | 37.02% |
| EBITDA | 23.50% | 16.73% | 44.63% | 38.06% | 38.38% |
| EPS Basic | 99.47% | 99.55% | -- | -- | -- |
| Normalized Basic EPS | 99.54% | -- | -- | -- | -- |
| EPS Diluted | 99.47% | 99.55% | -- | -- | -- |
| Normalized Diluted EPS | 99.54% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 21,144.44% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 21,144.44% | 18,008.00% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |